IRIS
TASSONE, PIERFRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.915
AS - Asia 3.145
EU - Europa 2.653
SA - Sud America 328
AF - Africa 58
Continente sconosciuto - Info sul continente non disponibili 25
OC - Oceania 18
Totale 12.142
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.639
SG - Singapore 1.757
IT - Italia 1.230
CN - Cina 877
SE - Svezia 401
GB - Regno Unito 343
DE - Germania 266
BR - Brasile 264
CA - Canada 231
IN - India 147
FI - Finlandia 95
HK - Hong Kong 59
NL - Olanda 54
FR - Francia 42
RO - Romania 36
VN - Vietnam 35
ES - Italia 34
BD - Bangladesh 32
MX - Messico 32
PK - Pakistan 29
RU - Federazione Russa 28
IQ - Iraq 23
JO - Giordania 23
JP - Giappone 23
UA - Ucraina 23
EU - Europa 22
PL - Polonia 21
ZA - Sudafrica 21
IR - Iran 19
TR - Turchia 19
ID - Indonesia 18
SA - Arabia Saudita 18
AR - Argentina 17
CZ - Repubblica Ceca 17
LT - Lituania 14
AT - Austria 13
AU - Australia 12
CO - Colombia 11
EG - Egitto 10
VE - Venezuela 10
AE - Emirati Arabi Uniti 9
CL - Cile 9
KR - Corea 9
PT - Portogallo 9
EC - Ecuador 8
ET - Etiopia 7
IE - Irlanda 7
MA - Marocco 7
MY - Malesia 7
EE - Estonia 6
LB - Libano 6
NG - Nigeria 5
CY - Cipro 4
IL - Israele 4
NZ - Nuova Zelanda 4
PH - Filippine 4
PS - Palestinian Territory 4
PY - Paraguay 4
TW - Taiwan 4
BG - Bulgaria 3
CH - Svizzera 3
GT - Guatemala 3
HN - Honduras 3
LK - Sri Lanka 3
PE - Perù 3
TN - Tunisia 3
TT - Trinidad e Tobago 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AZ - Azerbaigian 2
GR - Grecia 2
HR - Croazia 2
HU - Ungheria 2
KE - Kenya 2
NP - Nepal 2
SN - Senegal 2
UZ - Uzbekistan 2
AL - Albania 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CR - Costa Rica 1
DK - Danimarca 1
DZ - Algeria 1
GE - Georgia 1
JM - Giamaica 1
KI - Kiribati 1
KZ - Kazakistan 1
NI - Nicaragua 1
NR - Nauru 1
OM - Oman 1
PA - Panama 1
TH - Thailandia 1
TL - Timor Orientale 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 12.142
Salva come PNG Salva come JPEG
Città #
Chandler 906
Singapore 746
Santa Clara 452
Hefei 428
Milan 388
Lawrence 383
Princeton 383
Dallas 293
Chicago 269
London 248
Wilmington 224
Munich 209
Ashburn 208
Ottawa 165
Catanzaro 153
Des Moines 111
Boardman 84
Beijing 72
Turku 70
Los Angeles 63
Shanghai 48
Hong Kong 47
New York 46
Rome 44
Guangzhou 41
Pune 39
Norwalk 32
The Dalles 31
Redwood City 30
San Francisco 30
Brooklyn 29
Redmond 28
São Paulo 27
Council Bluffs 26
Naples 26
Helsinki 25
Montreal 20
Parma 19
Warsaw 19
Chennai 18
Columbus 18
Boston 17
San Nicola Manfredi 16
Stockholm 16
Amman 15
Atlanta 15
Phoenix 15
Charlotte 14
Manchester 14
Olomouc 14
West Jordan 14
Horia 13
Mountain View 13
Reggio Calabria 13
Amsterdam 12
Carbonia 12
Delhi 12
Denver 12
Mexico City 12
Palermo 12
Timisoara 12
Tokyo 12
Vallefiorita 12
Washington 12
Augusta 11
Cosenza 11
Hanover 11
Rio de Janeiro 11
Ho Chi Minh City 10
Johannesburg 10
Madrid 10
Seattle 10
Zhengzhou 10
Aversa 9
Dhaka 9
Hanoi 9
Jiaxing 9
Las Vegas 9
Shenzhen 9
Toronto 9
Afragola 8
Ahmedabad 8
Ankara 8
Bari 8
Cicciano 8
Ercolano 8
Irbid 8
San Jose 8
Santo Stefano di Rogliano 8
Xi'an 8
Baghdad 7
Jeddah 7
Kaunas 7
Ovada 7
Riyadh 7
Settingiano 7
Spezzano della Sila 7
Addis Ababa 6
Catania 6
Frankfurt am Main 6
Totale 7.111
Salva come PNG Salva come JPEG
Nome #
Pharmacogenetics/Pharmacogenomics of Drug-Metabolizing Enzymes and Transporters 377
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 100
miR-22 suppresses DNA ligase III addiction in multiple myeloma 88
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 85
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review 73
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. 70
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 66
Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis 64
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells in vitro 64
Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancer 64
A 5 ' regulatory sequence containing two Ets motifs controls the expression of the Wiskott-Aldrich syndrome protein (WASP) gene in human hematopoietic cells 62
Pyrrolo[2′,3′:3,4]cyclohepta[1,2- d][1,2]oxazoles, a New Class of Antimitotic Agents Active against Multiple Malignant Cell Types 61
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells 60
Non-coding RNAs in cancer: Platforms and strategies for investigating the genomic "dark matter" 60
An interleukin-6 antagonist modified for bone targeting preserves anti-myeloma biological activity 58
Raman Spectroscopic Stratification of Multiple Myeloma Patients Based on Exosome Profiling 58
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 58
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer 57
LNA-Gapmer Antisense Oligonucleotides Targeting the Oncogenic Lncrna MALAT1 Trigger Anti-Multiple Myeloma Activity By Proteasome Blockade 57
DMET-Analyzer: automatic analysis of Affymetrix DMET Data 56
Differential microRNAs expression profile in coronary thrombi from patients with no-reflow after primary PCI 56
Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease 55
Evidence of shared epitopic reactivity among independent B-cell clones in Chronic Lymphocytic Leukemia patients 54
Molecular and clinical types of plasma cell dyscrasias are associated with distinct expression patterns of long noncoding RNAs 53
Whole gene expression profiling shows a differential transcriptional response to CISPLATINUM in BRCA-1 defective versus BRCA1-reconstituted breast cancer cells 52
Aberrant Glycosylation as Biomarker for Cancer: Focus on CD43 52
Discovery, Functional Characterization and Therapeutic Targeting of Lnc-17-92 Metabolic Signaling in Multiple Myeloma 52
Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents 51
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling 51
Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data 51
Impact of natural dietary agents on multiple myeloma prevention and treatment: molecular insights and potential for clinical translation. 50
A novel monoclonal antibody recognizing human thymocytes and B-cell chronic lymphocytic leukemia cells 50
MIR-21 SUPPRESSION IMPAIRS TH17 RELATED BONE DISEASE IN MULTIPLE MYELOMA 50
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 50
Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment 50
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas 49
A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics 49
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 49
Distinctive germline expression of class i human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade 49
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. 48
Differential expression of UN1, early thymocyte-associated sialoglycoprotein, in breast normal tissue, benign disease and carcinomas 47
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 47
ACTIVATION OF GPER SIGNALING AS A POTENTIAL THERAPEUTIC STRATEGY AGAINST WALDENSTROM MACROGLOBULINEMIA 47
A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate? 46
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival 46
Biochemical modification of an Interleukin-6 antagonist to target myeloma cells in the bone marrow microenvironment 46
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma 45
Mir-34: a new weapon against cancer? 45
HLA class I, NKG2D and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells 45
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 45
DMET-miner: Efficient learning of association rules from genotyping data for personalized medicine 45
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report 45
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells 44
Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report 44
Anti-MALAT1 synthetic oligonucleotides target the proteasome and exert anti-multiple myeloma activity 44
Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation 43
Allometric scaling approaches for predicting human pharmacokinetic of a locked nucleic acid oligonucleotide targeting cancer-associated miR-221 43
DmetTM genotyping: Tools for biomarkers discovery in the era of precision medicine 43
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 42
Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia 42
Modulation of Exosomal microRNA in patients with severe Aortic Stenosis after Transcatheter Aortic Valve Implantation (TAVI) 42
Transcriptional regulation of the mismatch repair gene hMLH1 42
Associazione di antagonisti di IL-6 e farmaci anti-proliferativi (depositato il 10.3.2005 n. RM2005A000103) 42
Influence of the fabrication accuracy of hot-embossed PCL scaffolds on cell growths 42
Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab 42
Mir-22 modulates lenalidomide activity by counteracting myc addiction in multiple myeloma 42
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin 41
Mir-221/222 are promising targets for innovative anticancer therapy 41
Synthesis and preliminary evaluation of the anti-cancer activity on A549 lung cancer cells of a series of unsaturated disulfides. 41
[Extended subcutaneous mastectomy. A new type of operation in non-destructive surgery of breast neoplasms]. FT La mastectomia sottocutanea allargata. Un nuovo tipo d'intervento nella chirurgia non demolitiva della neoplasia mammaria. 41
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cellsBritish Journal of cancer 41
A35 SINGLE NUCLEOTIDE POLYMORPHISMS OF THE ABCG1 AND ABCC5 TRANSPORTER GENES CORRELATE TO IRINOTECAN-ASSOCIATED GASTROINTESTINAL TOXICITY IN COLORECTAL CANCER PATIENTS AS ASSESSED BY DMET MICROARRAY PROFILING 41
Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma 41
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis 41
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. 40
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it? 40
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up 40
Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against Waldenstrom Macroglobulinemia 40
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 40
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. 39
Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: The GOLFIG-2 multicentric open-label randomized phase III trial 39
A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias 39
A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma 39
Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC) 39
Polymorphic variants in NR1I3 and UGT2B7 predict taxane neurotoxicity and have prognostic relevance in breast cancer patients: a case-control study. 39
[Magnesium salts in the treatment of ventricular tachycardia]. FT I sali di magnesio nel trattamento della tachicardia ventricolare. 39
Evidence of shared epitopic reactivity among independent B-cell clones in chronic lymphocytic leukemia patients 39
Chromene Derivatives as Selective TERRA G-Quadruplex RNA Binders with Antiproliferative Properties 38
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma 38
Purification and characterization of a human sialoglycoprotein antigen expressed in immature thymocytes and fetal tissues 38
In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma 38
Second-line treatment of non-small cell lung cancer by biweekly gemcitabine and docetaxel plus /- granulocyte-macrophage colony stimulating factor and low dose aldesleukine 38
Mmrf-commpass data integration and analysis for identifying prognostic markers 38
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 38
JunB is a key regulator of multiple myeloma bone marrow angiogenesis 38
Oleil hydroxytyrosol (Htol) exerts anti-myeloma activity by antagonizing key survival pathways in malignant plasma cells 38
A MIR17HG-derived Long Noncoding RNA Provides an Essential Chromatin Scaffold for Protein Interaction and Myeloma Growth 37
A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer. 37
Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation 37
miR-221 stimulates breast cancer cells and cancer-associated fibroblasts (CAFs) through selective interference with the A20/c-Rel/CTGF signaling. 37
Totale 5.135
Salva come PNG Salva come JPEG
Categoria #
all - tutte 166.523
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 166.523
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021445 0 0 12 23 63 53 33 26 73 82 65 15
2021/20221.151 27 6 17 333 87 20 29 249 114 97 149 23
2022/20232.838 787 108 110 204 299 234 23 198 425 171 228 51
2023/20241.557 347 158 127 110 104 379 45 61 13 51 65 97
2024/20254.484 615 274 203 134 251 564 126 163 510 266 448 930
2025/20261.571 454 966 151 0 0 0 0 0 0 0 0 0
Totale 12.467